Abbisko Therapeutics Co

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Abbisko Therapeutics Co sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 4 currently recruiting early-phase tilt upper quartile by trial count

Abbisko Therapeutics Co: 6 sponsored US clinical trials, 4 recruiting.

Abbisko Therapeutics Co sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tenosynovial Giant Cell Tumor, with 2 trials.

Upper-quartile sponsor footprint

Abbisko Therapeutics Co sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

NCT06225804
RECRUITING Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

NCT05244551
RECRUITING Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

NCT04906434
RECRUITING Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

NCT04192344
ACTIVE NOT RECRUITING Phase 1

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

NCT05627063
ACTIVE NOT RECRUITING Phase 3

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

NCT05804045

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 3 1

Therapeutic Areas

Tenosynovial Giant Cell Tumor 2
Solid Tumor 2
Giant Cell Tumor of Tendon Sheath 1
Pigmented Villonodular Synovitis 1
Advanced Liver Cancer 1
Neoplasms 1
Non-Small Cell Lung Cancer 1

What is open in the Abbisko Therapeutics Co pipeline

4 recruiting of 6 indexed (67% open).

Phase mix: 1 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Tenosynovial Giant Cell Tumor (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Abbisko Therapeutics Co: open-pipeline peers nationwide

Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Abbisko Therapeutics Co sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Abbisko Therapeutics Co23andMeAardvark TherapeuticsAbGenomics B.V Taiwan BranchAbivax S.A.ABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery AllianceAlexander B Olawaiye, MD
Abbisko Therapeutics Co sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Abbisko Therapeutics Co sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Abbisko Therapeutics Co page

6 registered trials is a research-attention snapshot, not an endorsement of Abbisko Therapeutics Co or any single study.

  • 4 of Abbisko Therapeutics Co's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tenosynovial Giant Cell Tumor is the condition Abbisko Therapeutics Co studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tenosynovial Giant Cell Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Abbisko Therapeutics Co pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.